Key facts
- It has raised $52.3M across 2 recorded rounds; the latest was Early Stage VC ($11.2M) in Aug 2025.
- Notable investors include RA Capital Management, Hatteras Venture Partners, Eshelman Ventures, Boxer Capital, Cape Fear BioCapital — 7 tracked in total.
- Incyclix Bio has filed 3 Form Ds with the SEC since 2022, most recently Aug 2025 ($11.2M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Incyclix Bio
Funding rounds
2 roundsAbout Incyclix Bio
Developer of oncology therapeutics designed to advance precision treatments that target aberrant cell proliferation in cancer. The company's inhibitors help to achieve the potent and selective inhibition of elusive CDK targets, enabling oncology patients and healthcare providers access to targeted therapies for ovarian, breast, lung, and other tumor types to improve clinical outcomes.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2020
- Employees
- 10
- Website
- incyclixbio.com/
- Ownership
- Privately Held (backing)
Incyclix Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Incyclix Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Incyclix Bio in its N-PORT filings yet. We sweep new filings monthly.